| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,856 |
7,467 |
$463K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,969 |
4,229 |
$223K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,880 |
1,258 |
$203K |
| 80053 |
Comprehensive metabolic panel |
10,363 |
7,314 |
$187K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,874 |
1,407 |
$134K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,968 |
1,642 |
$107K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,450 |
1,274 |
$99K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,398 |
1,228 |
$94K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,037 |
1,581 |
$65K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
886 |
605 |
$59K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,274 |
7,440 |
$59K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,454 |
1,263 |
$51K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
789 |
687 |
$46K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,266 |
1,648 |
$34K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,291 |
564 |
$33K |
| 84703 |
|
2,980 |
2,558 |
$31K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,398 |
775 |
$30K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,371 |
548 |
$28K |
| 83735 |
|
5,828 |
3,947 |
$28K |
| 84484 |
|
2,408 |
1,753 |
$21K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
479 |
389 |
$19K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
358 |
183 |
$18K |
| G0378 |
Hospital observation service, per hour |
1,129 |
935 |
$17K |
| 80050 |
General health panel |
2,209 |
1,911 |
$17K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,362 |
4,398 |
$16K |
| 85610 |
|
954 |
663 |
$14K |
| 85027 |
|
2,915 |
1,965 |
$14K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
383 |
333 |
$13K |
| 84443 |
Thyroid stimulating hormone (TSH) |
970 |
853 |
$13K |
| 83690 |
|
2,553 |
2,171 |
$13K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,671 |
1,444 |
$13K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
797 |
743 |
$12K |
| 82947 |
|
1,744 |
920 |
$11K |
| 81001 |
|
3,232 |
2,750 |
$9K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
382 |
191 |
$9K |
| 81003 |
|
3,089 |
2,630 |
$9K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
30 |
25 |
$9K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
662 |
616 |
$8K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
115 |
98 |
$7K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
67 |
38 |
$7K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,531 |
1,102 |
$7K |
| 85379 |
|
808 |
702 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,336 |
1,467 |
$5K |
| 84100 |
|
1,610 |
1,116 |
$5K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
121 |
95 |
$5K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
90 |
80 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
78 |
55 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
129 |
109 |
$4K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
4,202 |
3,287 |
$4K |
| 80061 |
Lipid panel |
294 |
266 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
111 |
93 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
602 |
517 |
$3K |
| 71045 |
Radiologic examination, chest; single view |
2,906 |
2,513 |
$3K |
| 87428 |
|
82 |
74 |
$2K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
40 |
38 |
$2K |
| 80081 |
|
12 |
12 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
206 |
188 |
$2K |
| 80320 |
|
774 |
664 |
$2K |
| 82728 |
|
148 |
129 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
15,693 |
11,023 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,516 |
2,679 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
32 |
28 |
$1K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
15 |
12 |
$1K |
| 87070 |
|
42 |
37 |
$983.26 |
| 86850 |
|
162 |
137 |
$974.24 |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
22 |
12 |
$855.82 |
| 84439 |
|
108 |
94 |
$768.03 |
| 76642 |
|
27 |
25 |
$688.90 |
| 86803 |
|
34 |
28 |
$667.41 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
26 |
18 |
$625.59 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
16 |
12 |
$614.52 |
| 83540 |
|
87 |
69 |
$536.87 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
39 |
15 |
$512.85 |
| 86900 |
|
192 |
163 |
$423.93 |
| 81025 |
|
29 |
24 |
$411.89 |
| 84702 |
|
36 |
24 |
$363.46 |
| 83550 |
|
85 |
67 |
$354.69 |
| 83605 |
|
25 |
13 |
$351.51 |
| 83880 |
|
16 |
14 |
$344.06 |
| 87040 |
|
52 |
30 |
$343.26 |
| 86901 |
|
197 |
167 |
$324.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
4,311 |
3,188 |
$281.47 |
| 87186 |
|
59 |
36 |
$278.05 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
13 |
12 |
$254.79 |
| 82550 |
|
51 |
37 |
$250.43 |
| 84146 |
|
13 |
13 |
$233.21 |
| 96376 |
|
773 |
513 |
$152.77 |
| 87077 |
|
16 |
13 |
$105.92 |
| 82570 |
|
17 |
13 |
$60.97 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,892 |
2,338 |
$48.42 |
| 86140 |
|
14 |
13 |
$43.61 |
| 84132 |
|
15 |
14 |
$39.61 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
91 |
52 |
$5.88 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
636 |
544 |
$4.12 |
| 80329 |
|
87 |
81 |
$2.06 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,400 |
1,024 |
$1.83 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,567 |
991 |
$1.09 |
| A9270 |
Non-covered item or service |
686 |
379 |
$1.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,702 |
1,326 |
$0.89 |
| J7999 |
Compounded drug, not otherwise classified |
616 |
402 |
$0.73 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,186 |
2,437 |
$0.35 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,962 |
1,415 |
$0.35 |
| J2704 |
Injection, propofol, 10 mg |
78 |
63 |
$0.16 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
62 |
26 |
$0.03 |
| J2060 |
Injection, lorazepam, 2 mg |
367 |
276 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
169 |
138 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
139 |
92 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
55 |
43 |
$0.00 |
| 94760 |
|
82 |
71 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
62 |
51 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
1,390 |
1,112 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
303 |
237 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
67 |
53 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
36 |
12 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
127 |
81 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
15 |
13 |
$0.00 |